Autoantibodies to stratify systemic sclerosis patients into clinically actionable subsets

Michael Mahler, Marie Hudson, Chelsea Bentow, Fabrece Roup, Lorenzo Beretta, Carmen Pilar Simeón, Alfredo Guillén-Del-Castillo, Silva Casas, Marvin J. Fritzler

Research output: Contribution to journalReview article

Abstract

Systemic sclerosis (SSc) is a rare chronic disease of unknown etiology characterized by vascular abnormalities and fibrosis involving the skin and internal organs, especially the gastrointestinal tract, lung, heart and kidneys. Although the disease was historically stratified according to the extent of skin involvement, more recent approaches place more emphasis on patterns and extent of internal organ involvement. Despite numerous clinical trials in SSc, disease-modifying treatment options are still limited resulting in persistent poor quality of life and high mortality. This review provides an overview of autoantibodies in SSc and novel approaches to stratify the disease into clinically actionable subsets.

Original languageEnglish
Article number102583
JournalAutoimmunity Reviews
Volume19
Issue number8
DOIs
Publication statusPublished - 2020

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Autoantibodies to stratify systemic sclerosis patients into clinically actionable subsets'. Together they form a unique fingerprint.

  • Cite this

    Mahler, M., Hudson, M., Bentow, C., Roup, F., Beretta, L., Simeón, C. P., Guillén-Del-Castillo, A., Casas, S., & Fritzler, M. J. (2020). Autoantibodies to stratify systemic sclerosis patients into clinically actionable subsets. Autoimmunity Reviews, 19(8), [102583]. https://doi.org/10.1016/j.autrev.2020.102583